ANDERSON, ROBERT PAUL,HILL, ADRIAN VIVIAN SINTON,JEWELL, DEREK PARRY
申请号：
CA2386089
公开号：
CA2386089C
申请日:
2000.10.02
申请国别(地区):
CA
年份:
2016
代理人:
摘要：
A method of diagnosing coeliac disease, or susceptibility to coeliac disease,in an individual comprising : (a) contacting a sample from the host with anagent selected from (i) the epitope comprising sequence which is : SEQ ID NO :1 or 2, or an equivalent sequence from a naturally occurring homologue of thegliadin represented by SEQ ID NO : 3, (ii) an epitope comprising sequencecomprising : SEQ ID NO : 1, or an equivalent sequence from a naturallyoccurring homologue of the gliadin represented by SEQ ID NO : 3, which epitopeis an isolated oligopeptide derived from a gliadin protein, (iii) an analogueof (i) or (ii) which is capable of being recognised by a T cell receptor thatrecognises (i) or (ii), which in the case of a peptide analogue is not morethan 50 amino acids in length, or (iv) a product comprising two or more agentsas defined in (i), (ii) or (iii), and (b) determining in vitro whether T cellsin the sample recognise the agent； recognition by the T cells indicating thatthe individual has, or is susceptible to, coeliac disease. Therapeuticcompositions which comprise the epitope and gliadin proteins which do notcause coeliac disease are also provided.
